PSMA antibody, humanized PSMA.CAR10.3, or Cetuximab increases prostate cancer localization of NF-κB p50-deficient immature myeloid cells (p50-IMC) and phagocytosis by their macrophage progeny.
Saved in:
| Title: | PSMA antibody, humanized PSMA.CAR10.3, or Cetuximab increases prostate cancer localization of NF-κB p50-deficient immature myeloid cells (p50-IMC) and phagocytosis by their macrophage progeny. |
|---|---|
| Authors: | Alzubi MA; Division of Pediatric Oncology, Department of Oncology, Johns Hopkins University, CRB I, Rm. 253, 1650 Orleans St., Baltimore, MD, 21231, USA., Barberi T; Division of Pediatric Oncology, Department of Oncology, Johns Hopkins University, CRB I, Rm. 253, 1650 Orleans St., Baltimore, MD, 21231, USA., Friedman AD; Division of Pediatric Oncology, Department of Oncology, Johns Hopkins University, CRB I, Rm. 253, 1650 Orleans St., Baltimore, MD, 21231, USA. afriedm2@jhmi.edu. |
| Source: | Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2025 Feb 04; Vol. 74 (3), pp. 95. Date of Electronic Publication: 2025 Feb 04. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Springer Verlag Country of Publication: Germany NLM ID: 8605732 Publication Model: Electronic Cited Medium: Internet ISSN: 1432-0851 (Electronic) Linking ISSN: 03407004 NLM ISO Abbreviation: Cancer Immunol Immunother Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
